---
title: "Lysergide (DT120) in Generalized anxiety disorder: MMED008"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: MMED008. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 105 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence/mmed008"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: MMED008

<a id="heading-3.1.3"></a>

## 3.1.3 MMED008

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Objective stated in the publication

> “To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD.”
> “The current phase 2b study assessed the dose response, efficacy, safety, and tolerability of a single treatment with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 vs placebo in participants with moderate to severe GAD.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.1-2"></a>

#### Primary, key secondary, and exploratory objectives in the protocol

> “To determine the dose-response signal and assess the dose-response relationship of 4 doses of MM-120 (25, 50, 100, or 200 μg freebase-equivalent) as measured by the change in HAM-A Total Score from Baseline to Week 4”
> “To determine the dose-response signal and assess the dose-response relationship of 4 doses of MM-120 (25, 50, 100, or 200 μg freebase-equivalent) as measured by the change in HAM-A Total Score from Baseline to Week 8”
> “To explore the effect of MM-120 on direct and indirect health-care resource utilization (HCRU) and associated costs”
> “To assess blind integrity and to examine whether guess rates are associated with outcomes such as AEs or mood/anxiety symptoms”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.1-3"></a>

#### Registered study purpose

> “This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).”

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.1-4"></a>

#### Sponsor statement of the primary and key secondary objectives

> “The study's main objective was to determine the dose-response relationship of four doses of MM120 versus placebo as measured by the change in HAM-A from Baseline to Week 4. The key secondary objective of the study was to determine the dose-response relationship of four doses of MM120 versus placebo as measured by the change in HAM-A from Baseline to Week 8.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Study dates in the registry

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2022-08-24” |
| Primary completion (actual) | “2023-10-06” |
| Study completion (actual) | “2023-11-27” |
| First posted | “2022-06-07” |
| Results first posted | “2025-03-20” |

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.2-2"></a>

#### Registered locations

> “This study has 22 locations”

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.2-3"></a>

#### Sites and conduct period reported in the publication

> “was conducted at 22 outpatient psychiatric research sites in the US from August 2022 to August 2023.”
> “The last date of follow-up was November 27, 2023.”
> “The study was conducted at 22 outpatient psychiatric research sites across the US (eTable 2 in Supplement 3).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.2-4"></a>

#### First participant dosed, August 2022

> “today announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), for the treatment of Generalized Anxiety Disorder (GAD).”

Source: [MindMed Phase 2b first patient dosed announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/29/mindmed-announces-first-patient-dosed-in-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="topic-3.1.3.2-5"></a>

#### Completion of enrollment, September 2023

> “announced today that it has completed enrollment and dosing in Study MMED008, the Company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD.”

Source: [MindMed Phase 2b enrollment completion announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/125/mindmed-completes-enrollment-of-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.2-6"></a>

#### Number of clinical sites at completion of enrollment, September 2023, superseded in September 2025

> “198 participants dosed across 20 clinical sites”

Source: [MindMed Phase 2b enrollment completion announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/125/mindmed-completes-enrollment-of-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.2-7"></a>

#### Topline Week 4 results, December 2023

> “today announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD).”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="topic-3.1.3.2-8"></a>

#### Topline Week 12 results, March 2024

> “The Company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

<a id="topic-3.1.3.2-9"></a>

#### Journal publication, September 2025

> “Published Online: September 4, 2025.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Phase 2b randomized, double-blind, placebo-controlled, five-arm dose-finding design

> “In this phase 2b, multicenter, double-blind, placebo-controlled trial, participants with GAD were randomized equally to receive a single (freebase equivalent) treatment dose with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 or placebo without stratification (Figure 1).”
> “The study included 3 phases: (1) eligibility assessment (up to 35 days), (2) randomization (1 day), and (3) follow-up (12 weeks) (eFigure 1 in Supplement 3).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.3-2"></a>

#### Randomization and masking

> “Participants were equally randomized to 1 of 4 MM120 doses or placebo using a double-blind masking technique. Randomization was done centrally, using interactive response technology. All doses of MM120 and placebo were packaged identically.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.3-3"></a>

#### Protocol design and allocation ratio

> “This is a Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding clinical study that will assess the effect of 4 doses of MM-120 (25, 50, 100 or 200 μg freebase-equivalent) in comparison to placebo on anxiety symptoms in subjects diagnosed with GAD.”
> “Eligible subjects will be randomized in a 1:1:1:1:1 ratio to receive a single dose of either investigational drug (25, 50, 100 or 200 μg MM-120 freebase-equivalent) or placebo in a controlled clinical setting, which will be administered during the Dosing Session (Visit 3B) on Day 1.”
> “After Day 1/Randomization & Dosing Session (Visits 3A & 3B), subjects will have scheduled visits on Day 2 (Visit 4), Week 1 (Visit 5), Week 2 (Visit 6), Week 4 (Visit 7), Week 8 (Visit 8) and Week 12 (Visit 9).”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.3-4"></a>

#### Registry design fields

| Field | Registry record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Phase | “Phase 2” |
| Other study ID | “MMED008” |

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.3-5"></a>

#### Rationale for the dose levels and the placebo control

> “The 4 individual dose levels of MM-120 in the current study have been selected to assess both: 1) the dose-response relationship over a wide dose range that has been previously shown to be safe in clinical trials; and 2) the functional mechanism of action, specifically the extent to which psychedelic effects mediate clinical outcomes.”
> “Placebo control – an inactive placebo is the most appropriate control for the Multiple Comparison Procedure-Modelling (MCP-Mod) statistical approach to be used in the current study and for characterization of dose-response”
> “Threshold dose – minimum dose at which psychoactive effects are perceivable by patients on average”
> “The Sponsor concluded that no further dose increase beyond 200 μg (freebase-equivalent) would be required for predicted changes on HAM-A.”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

> “The MM120 dose levels in this study (freebase-equivalent dose of 0, 25, 50, 100, or 200 μg) have been explored in previous studies and found to bracket levels of acute drug effects with 25 μg at the threshold of perception, 50 μg producing reliable acute effects, 100 μg representing a ceiling for”
> “and 200 μg sometimes leading to increased levels of effects perceived as less pleasant.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.3-6"></a>

#### Blinded central rating of efficacy outcomes

> “The HAM-A and the Montgomery-Åsberg Depression Rating Scale (MADRS) scores were assessed by independent central raters via telephone; the raters were blinded to the trial protocol, treatment allocation, and study visit.”
> “To mitigate bias, the dosing session monitors were prohibited from conducting the efficacy assessments.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.3-7"></a>

#### Single administration with no psychotherapeutic intervention

> “Study MMED008 is a multi-center, parallel, randomized, double-blind, placebo-controlled, dose-optimization study.”
> “MM-120 was administered as a single-dose in a monitored clinical setting with no additional therapeutic intervention.”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

> “Five-arm dose optimization design with 1:1:1:1:1 randomization”
> “No changes planned to drug delivery between Phase 2 and Phase 3”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Key eligibility criteria reported in the publication

> “The eligibility criteria included age of 18 to 74 years, having a Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) primary diagnosis of GAD based on investigator assessment and confirmed by a Mini-International Neuropsychiatric Interview, and having moderate to severe anxiety (Hamilton Anxiety Rating Scale [HAM-A] score of ≥20) at both screening and at baseline.”
> “The exclusion criteria included contraindicated medical or psychiatric conditions and inability or unwillingness to discontinue therapeutics with potential drug-drug interaction or anxiolytic effects.”
> “Disclosure or detection of the use of prohibited substances, including tetrahydrocannabinol, was cause for screening failure or discontinuation as was the use of any psychedelic within the past 2 years or more than 10 times within the past 10 years.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.4-2"></a>

#### Inclusion criteria in the protocol

| Criterion | Quoted protocol text |
| --- | --- |
| Age | “Age ≥ 18 to < 75 years at Screening (Visit 1)” |
| Body weight | “Body weight of ≥ 50 kg” |
| Body mass index | “Body mass index [BMI] ≥ 18 to ≤ 38 mg/kg2” |
| Diagnosis | “Diagnosis of DSM-5 generalized anxiety disorder based upon clinical assessment and confirmed by the Mini-International Neuropsychiatric Interview (MINI)” |
| Anxiety severity | “HAM-A Total Score ≥ 20 at Screening (Visit 1) and Baseline (Visit 2)” |
| Medical condition | “Acceptable overall medical condition to be safely enrolled into and to complete the study, at the discretion of the Investigator” |
| Formulation | “Ability to swallow capsules” |

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.4-3"></a>

#### Key exclusion criteria in the protocol: psychiatric history and substance use

> “Prior history (lifetime diagnosis) or known first-degree relative (i.e., mother/father/full siblings) with a lifetime diagnosis of schizophrenia spectrum, or other psychotic disorder or bipolar disorder (bipolar I, bipolar II or cyclothymic disorder)”
> “Lifetime diagnosis of Posttraumatic Stress Disorder”
> “Other current psychiatric disorders that, in the opinion of the Investigator, may confound the results of the study (e.g., major depressive disorder, obsessive-compulsive disorder,”
> “History of alcohol or substance use disorder within 12 months prior to Screening (Visit 1) (includes diagnosis of alcohol or drug use disorder per the MINI)”
> “Unwillingness or inability to discontinue prohibited concomitant medications, supplements or other therapeutics (prescription or over-the-counter)”
> “Treatment with deep brain stimulation (DBS), vagus nerve stimulation (VNS), electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within 3 months prior to Screening (Visit 1) or a plan to receive treatment with any of these from the time of providing informed consent until End of Study”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.4-4"></a>

#### Key exclusion criteria in the protocol: cardiovascular conditions

> “Uncontrolled hypertension”
> “Blood pressure (BP) outside the range of 90-140 mmHg systolic BP or 50-90 mmHg diastolic BP after an approximately 5 minutes of rest”
> “Heart rate <45 beats/minute or >90 beats/minute after an approximately 5-minute supine rest at Screening and Baseline”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.4-5"></a>

#### Suicide risk exclusion in the registry

> “Has a significant risk of suicide attempt based upon medical history or has active suicidal ideation”

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.4-6"></a>

#### Concurrent psychotherapy

> “Participants undergoing psychotherapy at the time of screening could enroll but could not discontinue or modify session frequency during the study. Participants not receiving psychotherapy at screening could not initiate it during the trial.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Treatment arms in the registry

| Arm | Registry record |
| --- | --- |
| Placebo | “Placebo Comparator: Arm 1- Placebo” |
| Lysergide 25 µg | “Experimental: Arm 2- 25 μg MM120” |
| Lysergide 50 µg | “Experimental: Arm 3- 50 μg MM120” |
| Lysergide 100 µg | “Experimental: Arm 4- 100 μg MM120” |
| Lysergide 200 µg | “Experimental: Arm 5- 200 μg MM120” |
| Intervention description | “A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).” |

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.5-2"></a>

#### Number randomized to each arm

> “Participants were randomized to receive a single (freebase equivalent) treatment dose with 25 µg (n = 39), 50 µg (n = 40), 100 µg (n = 40), or 200 µg (n = 40) of MM120 or placebo (n = 39).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.5-3"></a>

#### Capsule formulation and blinded dose preparation

> “MM120 drug product is a solid oral capsule that was produced by granulating LSD with inactive excipients and filling approximately 80 mg of granulation powder into a hypromellose capsule. It was manufactured by Quotient Sciences. Each MM120 capsule was formulated to contain 36.6 μg of LSD (equivalent to 25 μg lysergide freebase), and each capsule batch met the uniformity of dosage-unit requirements set forth in United States Pharmacopeia (USP)”
> “Each dose was prepared by placing 8 total capsules in a closed, desiccated, high-density polyethylene bottle. A combination of MM120 and matching placebo capsules was placed in each bottle to achieve the specified MM120 freebase-equivalent dose of 0, 25, 50, 100, or 200 μg.”
> “Each participant received 8 capsules, which were swallowed with water.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.5-4"></a>

#### Formulation relative to the phase 3 trials

> “The dose-response results support the selection of MM120 100 µg for the Company’s ongoing Phase 3 development program for MM120 Orally Disintegrating Tablet (ODT).”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.5-5"></a>

#### Medication taper and washout before dosing

> “Participants taking mood or anxiety medications at screening were required to discontinue them under the supervision of site physicians. Before the baseline visit, a medication washout period of 5 half-lives or greater was required.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “Prior to treatment with MM120, study participants were clinically tapered and then washed out from any anxiolytic or antidepressant treatments and did not receive any form of study-related psychotherapy for the duration of their participation in the study.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

<a id="topic-3.1.3.5-6"></a>

#### Prohibited medications during the study

> “Categories of pharmacotherapies not permitted during the study were antipsychotics, antidepressants, barbiturates, benzodiazepines (except if indicated during the dosing session to manage AEs), cannabis, lithium, psychostimulants, and other substances known to affect serotonergic function (eg, efavirenz, kava, ginkgo biloba, St. John’s wort, and 5-hydroxytryptophan). Participants who took prohibited medication during the trial were discontinued.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.5-7"></a>

#### Dosing session procedures and monitoring

> “On the dosing day, participants received a single oral dose of MM120 or placebo. Each participant was continuously monitored on-site for safety and comfort by the same 2 dosing session monitors who conducted the participant’s educational session during the baseline visit.”
> “Participant dosing sessions were conducted individually in a private aesthetically pleasant room. The dosing sessions were not recorded or conducted in a group setting. Participants were offered standardized music and eyeshades and they could lie down, move freely around the room, read, write, or draw.”
> “Vital signs were measured throughout the dosing session and a physician was on-site in case comfort medications were needed.”
> “Engaging in psychotherapy with the participant was explicitly prohibited by the trial protocol (Supplement 1). Starting 8 hours after the dose, participants were assessed hourly to characterize the resolution of the drug effects. Continuous monitoring was required for a minimum of 12 hours.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.5-8"></a>

#### Dosing session monitor qualifications

> “The lead DSM was a licensed healthcare provider with graduate-level professional training and clinical experience.”
> “The secondary monitor had to have a bachelor's degree and a year of clinical experience.”
> “We approved 91 lead DSMs and 41 secondary DSMs.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.5-9"></a>

#### Release from the dosing session

> “Study subjects will be kept under continuous observation for a minimum of 12 hours following investigational drug administration. Beginning approximately 8 hours after drug administration, the Dosing Release Checklist will be performed by the site-designated licensed physician (MD/DO) to evaluate the subject’s psychological and physiological status. This will include an evaluation to ascertain that the subject no longer meets DSM-5 criteria for Hallucinogen Intoxication.”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Hamilton Anxiety Rating Scale Dose-Response at Week 4 as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Primary endpoint definition

> “The primary outcome was a dose-response relationship assessed using the multiple comparison procedure modeling (MCP-Mod) method for change in HAM-A score at 4 weeks (score range, 0-56; higher scores indicate greater severity; ≤7 indicates no or minimal anxiety; 8-14, mild; 15-23, moderate; and ≥24, severe).”
> “The HAM-A score was assessed by independent central raters using the Structured Interview Guide for the Hamilton Anxiety Rating Scale.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.6.1-2"></a>

##### Registered primary outcome and HAM-A items

> “To investigate the dose-response relationship for different doses of MM120 versus placebo in change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 4.”
> “The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general).”
> “Minimum score = 0, maximum score = 56.”

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.6.1-3"></a>

##### Protocol rationale for the HAM-A as the efficacy measure

> “The primary outcome measure for this study is the Hamilton Anxiety Rating Scale (HAM-A); a validated anxiety rating scale that has been used extensively in clinical trials (including numerous FDA registration trials) to assess anxiety symptoms across a range of psychiatric diagnoses”
> “The change in HAM-A score from baseline to post-treatment was used as the primary efficacy endpoint supporting approval of venlafaxine, paroxetine, escitalopram and duloxetine.”
> “Based on the myriad of patient populations that are sensitive to the HAM-A, the long history of use in new drug application enabling clinical trials and established validity, the HAM-A scale is fit-for-purpose to assess anxiety symptoms in subjects with GAD.”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.6.1-4"></a>

##### Protocol rationale for the Week 4 time point, the Week 8 key secondary endpoint, and the HAM-A entry threshold

> “The primary endpoint for the current study is change in HAM-A Total Score from Baseline to Week 4. Preliminary evidence suggests that LSD (along with other psychedelic therapies such as psilocybin) are rapid-acting, and that acute responses to treatment are predictive of intermediate and longer-term outcomes”
> “To assess the durability of effect, the key secondary endpoint of change in HAM-A Total Score from Baseline to Week 8 will be used.”
> “Eligibility for this study is based in part on a minimum HAM-A Total Score of 20. This is to target enrollment to a population of subjects who have significant anxiety that is sensitive to measurement by the HAM-A.”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.6.1-5"></a>

##### Rationale for the MCP-Mod analysis and the minimal clinically important difference

> “The primary outcome and the key secondary outcome were evaluated using the MCP-Mod approach at the 5% significance level, which integrates hypothesis testing with dose-response modeling and is endorsed by regulatory agencies for dose selection.”
> “A placebo-adjusted difference of 2.5 points for change in HAM-A score was used as the threshold (minimal clinically important difference of 2.5 points) for determining the minimally efficacious dose.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.6.1-6"></a>

##### Key secondary, secondary, and exploratory endpoints

> “The key secondary outcome was a dose-response relationship”
> “assessed using the MCP-Mod method for change in HAM-A score at 8 weeks.”
> “The rates of response (≥50% change [reduction] in HAM-A score from baseline) and remission (HAM-A score ≤7) were also explored.”
> “The effects of MM120 on functional disability, quality of life, and sexual function were assessed throughout the trial using the Sheehan Disability Scale, the EuroQol 5-dimension 5-level questionnaire, the Pittsburgh Sleep Quality Index, and the Arizona Sexual Experiences Questionnaire.”
> “Blinding of the participants and raters regarding treatment allocation (active drug, placebo, or indiscernible) was assessed using a 5-point questionnaire (range, 1 [positive they received drug] to 5 [positive they received placebo]).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.6.1-7"></a>

##### Safety endpoints

> “Safety and tolerability were evaluated through adverse event (AE) monitoring, physical and neuropsychiatric examinations, vital signs, electrocardiographic monitoring, and laboratory tests. Suicidal ideation and behavior were assessed at each visit using the Columbia–Suicide Severity Rating Scale (C-SSRS).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned sample size and power

> “To achieve a mean power greater than 87% for the MCP-Mod approach analysis, 200 participants were planned to yield at least 180 evaluable end points after any dropouts.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.7.1-2"></a>

##### Target sample size in protocol version 6.0, July 2023

> “The target sample size for this study is approximately 180 subjects.”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.7.1-3"></a>

##### Planned enrollment in the registry description

> “The study will enroll approximately 200 male and female subjects 18 years to < 75 years of age who meet DSM-5 criteria for GAD and have a minimum HAM-A Total Score of 20.”

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.7.1-4"></a>

##### Planned enrollment at first participant dosing, August 2022

> “The trial plans to enroll 200 participants who will receive a single administration of up to 200 µg of MM-120 or placebo.”

Source: [MindMed Phase 2b first patient dosed announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/29/mindmed-announces-first-patient-dosed-in-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="topic-3.1.3.7.1-5"></a>

##### Participants randomized and analyzed

> “There were 198 participants in the Randomized Set and 198 participants in the Safety Set. Of these, 194 (98.0%) of participants were included in the Full Analysis Set and 183 (92.4%) were included in the Per Protocol Set.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

> “Of the 198 participants randomized, 194 were included in the full analysis set”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Analysis sets used for efficacy and safety

> “Efficacy was analyzed in the full analysis set, which was composed of all randomized participants with a HAM-A measurement at baseline and at least 1 HAM-A measurement after baseline. Safety was evaluated in all participants who were randomized.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.7.2-2"></a>

##### Analysis sets defined in the statistical analysis plan

> “Randomized Set (RAN) – all subjects who received a randomization number, regardless of receiving study drug.”
> “Safety Set (SAF) – all subjects who received the double-blind study drug. Subjects will be analyzed according to the actual treatment received.”
> “Full Analysis Set (FAS) – all randomized subjects with a valid baseline HAM-A assessment and at least one valid post-baseline HAM-A assessment.”
> “Per Protocol Set (PPS) - All subjects in the full analysis set who had no major protocol deviations deemed as impacting the primary endpoint.”

Source: [MindMed MMED008 statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/SAP_001.pdf)

<a id="topic-3.1.3.7.2-3"></a>

##### MCP-Mod testing procedure and dose-response models

> “Six candidate dose-response models were prespecified to represent a range of plausible dose-response shapes”
> “assessed under strict type I error control at the 5% level using a hierarchical gatekeeping testing procedure.”
> “The estimated dose-response curve was derived using an Akaike information criterion–weighted average of the top 3 dose-response models.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.7.2-4"></a>

##### Handling of missing data and intercurrent events

> “Missing primary end point data were imputed using multiple imputations with 20 iterations. Observations missing due to prohibited medication use were assumed to be missing not at random and imputed using placebo-based imputation. All other missing observations were imputed under the assumption of missing at random.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.7.2-5"></a>

##### Secondary analyses without imputation or multiplicity adjustment

> “Change in HAM-A score from baseline was analyzed using an analysis of covariance model adjusted for the baseline values and treatment group without imputation (observed cases only).”
> “Other secondary efficacy outcomes were analyzed using 2-sample t tests.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “Missing data was not imputed for analysis of non-key secondary efficacy endpoints or safety endpoints. No adjustment for multiplicity was performed for testing the non-key secondary and exploratory endpoints.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.7.2-6"></a>

##### Effect size calculation

> “Cohen d was calculated as the bias-corrected least-squares estimate of the treatment difference in changes from baseline to a given time point (from an analysis of covariance model), divided by the pooled SD of observed values at the same time point from a given active dose group and the placebo group.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Screening, randomization, and study completion

> “A total of 554 potential participants were screened and 356 were excluded. Of the 198 participants randomized to study treatment, 147 (74.2%) completed the study.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.1-2"></a>

##### Completion by arm in the registry

| Arm | Started | Completed | Not completed |
| --- | --- | --- | --- |
| Placebo | “39” | “26” | “13” |
| Lysergide 25 µg | “39” | “29” | “10” |
| Lysergide 50 µg | “40” | “29” | “11” |
| Lysergide 100 µg | “40” | “33” | “7” |
| Lysergide 200 µg | “40” | “30” | “10” |

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.1-3"></a>

##### Enrollment period and randomization in the publication

> “Between August 24, 2022, and August 30, 2023, a total of 554 participants were screened; of these, 198 were randomized and received a single (freebase equivalent) treatment dose with 25 µg (n = 39), 50 µg (n = 40), 100 µg (n = 40), or 200 µg (n = 40) of MM120 or placebo (n = 39) (Figure 1).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.1-4"></a>

##### Withdrawals due to adverse events

> “Five participants (2.5%) withdrew due to AEs (2 participants each in the 25-µg and 50-µg dose groups and 1 participant in the 100-µg group).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.1-5"></a>

##### Sponsor summary of completion rates

> “74% 12-week completion rate of all randomized participants which is consistent with other studies in drug class”
> “79% 12-week completion rate in high dose groups”
> “Included in FAS population: 90%”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.3.8.1-6"></a>

##### Completion through Week 4 in the topline announcement

> “The overall four-week completion rate in the trial was approximately 90% and was 97.5% in the high dose groups, and no participants in the high dose groups discontinued due to an adverse event through Week 4.”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Demographics of the full analysis set

> “Of the 198 participants randomized, 194 were included in the full analysis set (mean age, 41.3 [SD, 13.6] years; 56.7% were female; and 3.6% were Asian, 7.7% were Black or African American, and 83.0% were White) (Table 1).”
> “The mean HAM-A scores at baseline were equivalent across groups (score range, 29.3-31.0).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.2-2"></a>

##### Baseline demographics and disease characteristics by arm

| Characteristic | Placebo (n = 39) | 25 µg (n = 39) | 50 µg (n = 36) | 100 µg (n = 40) | 200 µg (n = 40) |
| --- | --- | --- | --- | --- | --- |
| Age, median (IQR), y | “37 (28.5-47.5)” | “35 (30.5-43.0)” | “47 (33.0-57.3)” | “41 (29.0-55.5)” | “38.5 (33.8-55.0)” |
| Female, No. (%) | “26 (66.7)” | “20 (51.3)” | “20 (55.6)” | “16 (40.0)” | “28 (70.0)” |
| White, No. (%) | “30 (76.9)” | “33 (84.6)” | “29 (80.6)” | “36 (90.0)” | “33 (82.5)” |
| Black or African American, No. (%) | “6 (15.4)” | “3 (7.7)” | “2 (5.6)” | “1 (2.5)” | “3 (7.5)” |
| Hispanic or Latino, No. (%) | “8 (20.5)” | “5 (12.8)” | “6 (16.7)” | “6 (15.0)” | “6 (15.0)” |
| Time from GAD diagnosis, median (IQR), y | “11.0 (4.5-18.8)” | “7.0 (3.2-14.0)” | “12.9 (6.0-17.4)” | “11.2 (3.1-20.3)” | “11 (5.8-20.7)” |
| HAM-A score, mean (SD) | “30.3 (6.6)” | “30.2 (6.1)” | “30.3 (5.7)” | “29.3 (6.4)” | “31.0 (7.0)” |
| CGI-S score, mean (SD) | “4.9 (0.6)” | “4.9 (0.8)” | “4.9 (0.6)” | “4.8 (0.8)” | “5.1 (0.7)” |
| MADRS score, mean (SD) | “27.6 (9.7)” | “25.4 (7.6)” | “27.7 (8.3)” | “26.5 (8.0)” | “28.9 (8.3)” |
| Continued psychotherapy during trial, No. (%) | “9 (23.1)” | “3 (7.7)” | “11 (27.5)” | “5 (12.5)” | “7 (17.5)” |
| Comorbid major depression, No. (%) | “17 (43.6)” | “12 (30.8)” | “17 (47.2)” | “18 (45.0)” | “15 (37.5)” |
| Comorbid social anxiety disorder, No. (%) | “9 (23.1)” | “6 (15.4)” | “5 (13.9)” | “4 (10.0)” | “5 (12.5)” |
| Comorbid panic disorder, No. (%) | “7 (17.9)” | “5 (12.8)” | “4 (11.1)” | “2 (5.0)” | “5 (12.5)” |
| SSRI or SNRI taper at enrollment, No. (%) | “25 (64.1)” | “25 (64.1)” | “28 (77.8)” | “21 (52.5)” | “16 (40.0)” |
| Benzodiazepine taper at enrollment, No. (%) | “9 (23.1)” | “6 (15.4)” | “9 (25.0)” | “2 (5.0)” | “14 (35.0)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.2-3"></a>

##### Prior treatment and medication taper at screening

> “At screening, 84% of participants required tapering prohibited medications, 16% were treatment-naive, and 18% were receiving psychotherapy at the time of enrollment; psychotherapy was allowed to continue through the trial. Of the participants who required tapering prohibited medications, 43% were taking serotonin reuptake inhibitors, 34% were taking benzodiazepines, and 19% were taking antipsychotics or antiepileptics.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.2-4"></a>

##### Baseline severity described by the sponsor

> “Subjects enrolled in the trial presented with severe GAD symptoms (average baseline HAM-A scores of approximately 30).”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Primary endpoint: MCP-Mod dose-response for HAM-A change at Week 4

> “A significant MM120 dose-response relationship was demonstrated at both week 4 (primary outcome) and week 8 (key secondary outcome) based on changes from baseline in HAM-A score.”
> “At week 4, the adjusted critical value was 2.032 and the candidate dose-response models of sigmoid Emax 1 through 4, Emax, and linear observed absolute test statistics of 3.294, 3.149, 3.133, 1.448, 3.471, and 2.971, respectively. Therefore, 5 of the 6 models, including the linear, Emax, and multiple sigmoid Emax variants, met the significance threshold.”
> “For the primary outcome, the dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 4 was statistically significant for the 100-µg and the 200-µg dose groups vs placebo (least-squares mean difference, −5.0 points [95% CI, −9.6 to −0.4 points] with 100 µg of MM120 and −6.0 points [95% CI, −9.8 to −2.0 points] with 200 µg of MM120) but the 25-µg and 50-µg dose groups did not reach significance vs placebo (least-squares mean difference, −1.2 points [95% CI, −6.0 to 3.5 points] with 25 µg of MM120 and −1.8 points [95% CI, −7.6 to 4.0 points] with 50 µg of MM120)”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-2"></a>

##### Primary endpoint: model-based estimates at Week 4 by arm

| Arm | Least-squares mean change (95% CI) | Least-squares mean difference vs placebo (95% CI) |
| --- | --- | --- |
| Placebo | “−14.2 (−17.8 to −10.6)” | Not applicable |
| Lysergide 25 µg | “−15.4 (−17.6 to −13.1)” | “−1.2 (−6.0 to 3.5)” |
| Lysergide 50 µg | “−16.0 (−19.4 to −12.7)” | “−1.8 (−7.6 to 4.0)” |
| Lysergide 100 µg | “−19.2 (−21.7 to −16.7)” | “−5.0 (−9.6 to −0.4)” |
| Lysergide 200 µg | “−20.1 (−22.9 to −17.3)” | “−6.0 (−9.8 to −2.0)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-3"></a>

##### Primary endpoint as posted on the registry

| Arm | Mean change from baseline to Week 4, model averaging (95% CI) | Mean difference from placebo (95% CI) |
| --- | --- | --- |
| Placebo | “-14.23 (-17.83 to -10.63)” | Not applicable |
| Lysergide 25 µg | “-15.35 (-17.62 to -13.09)” | “-1.24 (-6.01 to 3.53)” |
| Lysergide 50 µg | “-16.05 (-19.40 to -12.71)” | “-1.82 (-7.65 to 4.00)” |
| Lysergide 100 µg | “-19.22 (-21.73 to -16.70)” | “-5.02 (-9.60 to -0.44)” |
| Lysergide 200 µg | “-20.09 (-22.87 to -17.31)” | “-5.95 (-9.84 to -2.06)” |

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.3-4"></a>

##### Minimally efficacious dose

> “These selected models at each time point were incorporated into an Akaike information criterion–weighted model-averaging procedure to estimate the dose-response curve and calculate the minimally efficacious dose, which was found to be between 56.7 µg and 85.1 µg (eFigure 2 in Supplement 3).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-5"></a>

##### Key secondary endpoint: MCP-Mod dose-response for HAM-A change at Week 8

> “At week 8, the adjusted critical value was 2.041 and the candidate dose-response models of sigmoid Emax 1 through 4, Emax, and linear observed absolute test statistics of 2.099, 2.922, 2.938, 2.254, 2.690, and 2.778, respectively. Therefore, all 6 models met the significance threshold, with the linear, Emax, and sigmoid Emax models selected as the best fitting.”
> “For the key secondary outcome, the dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 8 was statistically significant for the 100-µg and the 200-µg dose groups vs placebo (least-squares mean difference, −2.9 points [95% CI, −5.4 to −0.5 points] with 100 µg of MM120 and −5.4 points [95% CI, −9.5 to −1.4 points] with 200 µg of MM120) but”
> “the 25-µg and 50-µg dose groups did not reach significance vs placebo (least-squares mean difference, −0.8 points [95% CI, −1.7 to 0.2 points] with 25 µg of MM120 and −1.4 points [95% CI, −3.1 to 0.2 points] with 50 µg of MM120)”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-6"></a>

##### Week 4 HAM-A difference at 100 µg: observed-case ANCOVA secondary analysis in the publication

> “For the secondary outcome at week 4, the 100-µg and the 200-µg dose groups significantly reduced HAM-A score vs placebo (the least-squares mean difference was −7.6 points [95% CI, −11.8 to −3.4 points; P < .001; Cohen d = 0.88] with 100 µg of MM120 and was −5.5 points [95% CI, −9.7 to −1.3 points; P = .01; Cohen d = 0.64] with 200 µg of MM120)”
> “At week 4, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −3.4 points (95% CI, −7.7 to 0.9 points; P = .12) with 25 µg of MM120 and the reduction was −0.9 points (95% CI, −5.2 to 3.3 points; P = .66) with 50 µg of MM120.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-7"></a>

##### Week 4 HAM-A difference at 100 µg: company topline announcement, December 2023

> “MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, representing a 7.6-point improvement over placebo at Week 4 (p=0.0004, Cohen’s d effect size = 0.88)”
> “MM-120 100 µg – the dose achieving the highest level of clinical activity – demonstrated a 7.6-point reduction compared to placebo at Week 4 (-21.3 MM-120 vs. -13.7 placebo; p<0.0004; Cohen’s d=0.88).”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="topic-3.1.3.8.3-8"></a>

##### Week 4 HAM-A difference at 100 µg: company publication announcement, September 2025

> “At Week 4, it achieved a 7.6-point greater reduction in HAM-A scores compared to placebo (-21.3 vs. -13.7; p<0.0004; Cohen’s d=0.88) with a 65% clinical response rate and 48% clinical remission rate sustained to Week 12.”
> “MM120 100 and 200 µg significantly reduced HAM-A from baseline to Week 4 with placebo-adjusted improvement in HAM-A of -7.6 (95% CI, -11.8 to -3.4; p<0.001, and -5.50 (95% CI, -9.7 to -1.3; p=0.01) points, while 25 and 50 µg did not reach statistical significance, demonstrating placebo-adjusted improvements of -3.4 (95% CI, -7.7 to 0.9; p=0.12) and -0.9 (95% CI, -5.2 to 3.3; p=0.66).”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.8.3-9"></a>

##### HAM-A change from baseline by week: observed-case ANCOVA differences from placebo

| Week | 25 µg | 50 µg | 100 µg | 200 µg |
| --- | --- | --- | --- | --- |
| Week 1 | “−4.3 (−8.5 to −0.1)” | “−2.5 (−6.7 to 1.7)” | “−8.1 (−12.3 to −3.9)” | “−6.0 (−10.2 to −1.8)” |
| Week 2 | “−3.4 (−7.5 to 0.8)” | “−1.5 (−5.7 to 2.8)” | “−7.1 (−11.3 to −2.9)” | “−7.5 (−11.6 to −3.3)” |
| Week 4 | “−3.4 (−7.7 to 0.9)” | “−0.9 (−5.2 to 3.3)” | “−7.6 (−11.8 to −3.4)” | “−5.5 (−9.7 to −1.3)” |
| Week 8 | “−2.9 (−7.6 to 1.8)” | “0.85 (−3.9 to 5.6)” | “−4.3 (−8.9 to 0.3)” | “−5.5 (−10.2 to −0.8)” |
| Week 12 | “−4.3 (−9.3 to 0.8)” | “−3.2 (−8.2 to 1.9)” | “−7.7 (−12.6 to −2.8)” | “−7.4 (−12.4 to −2.4)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-10"></a>

##### HAM-A change at Weeks 8 and 12

> “For the secondary outcome at week 8, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −4.3 points (95% CI, −8.9 to 0.3 points; P = .06; Cohen d = 0.48) for 100 µg of MM120 and the reduction was −5.5 points (95% CI, −10.2 to −0.8 points; P = .02; Cohen d = 0.60) for 200 µg of MM120. At week 12, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −7.7 points (95% CI, −12.6 to −2.8 points; P = .003; Cohen d = 0.81) with 100 µg of MM120 and the reduction was −7.4 points (95% CI, −12.4 to −2.4 points; P = .004; Cohen d = 0.77) with 200 µg of MM120.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-11"></a>

##### HAM-A change at Week 12: company topline announcement, March 2024

> “MM120 100 µg – the dose with optimal clinical activity observed in the trial – demonstrated a 7.7-point improvement over placebo at Week 12 (-21.9 MM120 vs. -14.2 placebo; p<0.003 Cohen’s d=0.81), with a 65% clinical response rate and a 48% clinical remission rate sustained to Week 12.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

<a id="topic-3.1.3.8.3-12"></a>

##### HAM-A response and remission at Week 12

> “The secondary outcome of HAM-A response (defined by a 50% reduction in total score) at week 12 was achieved by 65.0% of participants in the 100-µg dose group and by 62.5% in the 200-µg dose group compared with 30.8% of participants in the placebo group and the remission rates at week 12 were 47.5%, 45.0%, and 20.5%, respectively (eFigure 4 and eTable 3 in Supplement 3).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-13"></a>

##### HAM-A response and remission at Weeks 4 and 12 by arm

| Outcome | Placebo (n=39) | 25 μg (n=39) | 50 μg (n=36) | 100 μg (n=40) | 200 μg (n=40) |
| --- | --- | --- | --- | --- | --- |
| Response, Week 4, n (%) | “12 (30.8%)” | “20 (51.3%)” | “21 (58.3%)” | “31 (77.5%)” | “31 (77.5%)” |
| Response, Week 12, n (%) | “12 (30.8%)” | “17 (43.6%)” | “20 (55.6%)” | “26 (65.0%)” | “25 (62.5%)” |
| Remission, Week 4, n (%) | “7 (17.9%)” | “11 (28.2%)” | “9 (25.0%)” | “20 (50.0%)” | “14 (35.0%)” |
| Remission, Week 12, n (%) | “8 (20.5%)” | “11 (28.2%)” | “12 (33.3%)” | “19 (47.5%)” | “18 (45.0%)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

> “HAM-A response was defined as ≥50% reduction in the HAM-A. HAM-A remission was defined as a HAM-A ≤7”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.3-14"></a>

##### HAM-A response and remission at Week 4: company topline announcement, December 2023

> “Clinical response (50% or greater improvement in HAM-A) at Week 4 was achieved in 78% of participants treated with MM-120 (100 µg or 200 µg) compared to 31% for placebo. Clinical remission (HAM-A ≤ 7) at Week 4 was achieved in 50% of participants treated with MM-120 100 µg.”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="topic-3.1.3.8.3-15"></a>

##### Clinician-rated illness severity (CGI-S)

> “The statistically significant improvements in illness severity (measured using the CGI-S score) were observed on day 2 and at weeks 2 through 12 in the 100-µg and 200-µg dose groups, but not in the 25-µg or 50-µg dose groups or in the placebo group. At week 1, all MM120 dose groups demonstrated significant improvements, but the placebo group did not”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-16"></a>

##### CGI-S mean difference from placebo on Day 2 and at Week 12

| Time point | 25 µg | 50 µg | 100 µg | 200 µg |
| --- | --- | --- | --- | --- |
| Day 2 | “−0.3 (−0.8 to 0.2)” | “−0.4 (−0.9 to 0.1)” | “−1.1 (−1.7 to −0.6)” | “−0.8 (−1.4 to −0.2)” |
| Week 12 | “−0.4 (−1.2 to 0.4)” | “−0.6 (−1.5 to 0.2)” | “−1.2 (−2.0 to −0.4)” | “−1.1 (−1.9 to −0.2)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-17"></a>

##### CGI-S change described by the sponsor

> “CGI-S scores on average improved from 4.8 to 2.2 in the 100 µg dose group, representing a two-category shift from ‘markedly ill’ to ‘borderline ill’ at Week 12, compared with 4.9 to 3.5 in the placebo group (p=0.003).”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

> “1.8-point reduction in CGI-S within 24 hours (p<0.0001)”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.3.8.3-18"></a>

##### Depressive symptoms (MADRS)

> “Significant improvement in depressive symptoms (as measured by MADRS score) was observed from weeks 1 through 12 in the 100-µg and 200-µg dose groups, but not in the 25-µg and 50-µg dose groups”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-19"></a>

##### MADRS mean difference from placebo at Weeks 4 and 12

| Week | 25 µg | 50 µg | 100 µg | 200 µg |
| --- | --- | --- | --- | --- |
| Week 4 | “1.0 (−4.4 to 6.4)” | “0.1 (−5.1 to 5.3)” | “−5.7 (−11.0 to −0.5)” | “−5.9 (−11.1 to −0.7)” |
| Week 12 | “−1.6 (−7.3 to 4.0)” | “−2.3 (−7.3 to 2.6)” | “−6.4 (−11.9 to −0.9)” | “−7.6 (−13.1 to −2.1)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-20"></a>

##### MADRS change described by the sponsor

> “MADRS score improvements in the 100 µg arm of the study were clinically and statistically significant compared to the placebo group, with a difference of 5.7 points (p≤0.05) at week 4 and a difference of 6.4 points (p≤0.05) at week 12.”

Source: [MindMed APA presentation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/144/mindmed-presents-phase-2b-study-of-mm120-for-generalized-anxiety-disorder-gad-at-american-psychiatric-association-apa-annual-meeting-in-new-york)

<a id="topic-3.1.3.8.3-21"></a>

##### Functional unblinding and placebo response

> “All doses of MM120 produced transient perceptual, cognitive, and emotional effects leading to participant unblinding.”
> “despite approximately 85% of participants correctly identifying assignment to active treatment.”
> “In addition, even though more than 65% of participants accurately identified their assignment as placebo recipients, a robust placebo effect was observed that was comparable with or exceeded trials of anxiolytics.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-22"></a>

##### Subgroup analyses

> “The analyses of the treatment response by sex and other participant characteristics were not conducted due to insufficient statistical power to evaluate meaningful differences within dosing groups.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

##### Functional, quality-of-life, sleep, and sexual function outcomes reported in the supplement

> “Additional secondary outcomes, including changes in scores for the Sheehan Disability Scale, the EuroQol 5-dimension 5-level questionnaire, the Pittsburgh Sleep Quality Index, and the Arizona Sexual Experiences Questionnaire appear in eTable 6 in Supplement 3.”
> “For the secondary outcomes focused on functional disability, the changes from baseline were analyzed descriptively.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.4-2"></a>

##### Sheehan Disability Scale total score at Week 12

| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
| --- | --- | --- | --- |
| Placebo | “-8.2 (8.61)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-10.8 (7.72)” | “-2.59” | “(-7.10 to 1.91)” |
| Lysergide 50 μg | “-9.0 (9.17)” | “-0.83” | “(-5.70 to 4.03)” |
| Lysergide 100 μg | “-15.1 (5.78)” | “-6.86” | “(-10.89 to -2.83)” |
| Lysergide 200 μg | “-13.1 (7.51)” | “-4.93” | “(-9.33 to -0.53)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.4-3"></a>

##### EQ-5D-5L visual analog scale at Week 12

| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
| --- | --- | --- | --- |
| Placebo | “11.7 (18.24)” | Not applicable | Not applicable |
| Lysergide 25 μg | “17.0 (18.53)” | “5.31” | “(-4.65 to 15.27)” |
| Lysergide 50 μg | “13.2 (13.97)” | “1.55” | “(-7.34 to 10.45)” |
| Lysergide 100 μg | “17.7 (13.68)” | “6.04” | “(-2.61 to 14.70)” |
| Lysergide 200 μg | “17.3 (19.40)” | “5.64” | “(-4.37 to 15.65)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.4-4"></a>

##### Pittsburgh Sleep Quality Index global score at Week 12

| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
| --- | --- | --- | --- |
| Placebo | “-4.3 (4.22)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-5.5 (4.01)” | “-1.25” | “(-3.48 to 0.99)” |
| Lysergide 50 μg | “-4.8 (3.88)” | “-0.55” | “(-2.77 to 1.67)” |
| Lysergide 100 μg | “-5.9 (4.13)” | “-1.64” | “(-3.84 to 0.56)” |
| Lysergide 200 μg | “-4.9 (4.11)” | “-0.60” | “(-2.83 to 1.62)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.4-5"></a>

##### Patient Global Impression of Severity and of Change at Week 12

| Arm | PGI-S difference from placebo in mean change | PGI-S 95% CI | PGI-C observed mean (SD) | PGI-C difference from placebo | PGI-C 95% CI |
| --- | --- | --- | --- | --- | --- |
| Placebo | Not applicable | Not applicable | “2.2 (0.98)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-0.34” | “(-0.91 to 0.24)” | “1.8 (0.71)” | “-0.36” | “(-0.83 to 0.10)” |
| Lysergide 50 μg | “-0.30” | “(-0.94 to 0.34)” | “1.8 (1.00)” | “-0.36” | “(-0.90 to 0.17)” |
| Lysergide 100 μg | “-0.47” | “(-1.05 to 0.11)” | “1.5 (0.67)” | “-0.71” | “(-1.16 to -0.25)” |
| Lysergide 200 μg | “-0.37” | “(-1.01 to 0.26)” | “1.7 (0.98)” | “-0.51” | “(-1.04 to 0.01)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.4-6"></a>

##### Sexual dysfunction (ASEX) at Week 12

| Arm | Females with sexual dysfunction, n (%) | Males with sexual dysfunction, n (%) |
| --- | --- | --- |
| Placebo | “6 (33.3)” | “1 (12.5)” |
| Lysergide 25 μg | “4 (25.0)” | “3 (23.1)” |
| Lysergide 50 μg | “10 (66.7)” | “1 (7.1)” |
| Lysergide 100 μg | “6 (46.2)” | “2 (10.0)” |
| Lysergide 200 μg | “7 (33.3)” | “0 (0)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Overview of adverse events

> “The rate for 1 or more treatment-emergent adverse events (TEAEs) was 76.9% in the 25 µg of MM120 group, was 90.0% in the 50-µg group, was 97.5% in the 100-µg group, and was 100% in the 200-µg group vs 56.4% in the placebo group (Table 3).”
> “Of all the AEs, 98.5% occurred on the dosing day and most resolved by the end of the dosing session.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.5-2"></a>

##### Adverse events in the safety population by arm

| Event, No. (%) | Placebo (n = 39) | 25 µg (n = 39) | 50 µg (n = 40) | 100 µg (n = 40) | 200 µg (n = 40) |
| --- | --- | --- | --- | --- | --- |
| At least 1 TEAE | “22 (56.4)” | “30 (76.9)” | “36 (90.0)” | “39 (97.5)” | “40 (100)” |
| Any treatment-related TEAE | “16 (41.0)” | “29 (74.4)” | “32 (80.0)” | “38 (95.0)” | “40 (100)” |
| Moderate AE | “10 (25.6)” | “12 (30.8)” | “20 (50.0)” | “23 (57.5)” | “28 (70.0)” |
| Visual perception changes | “4 (10.3)” | “18 (46.2)” | “30 (75.0)” | “37 (92.5)” | “40 (100)” |
| Nausea | “3 (7.7)” | “3 (7.7)” | “11 (27.5)” | “16 (40.0)” | “24 (60.0)” |
| Headache | “9 (23.1)” | “5 (12.8)” | “9 (22.5)” | “14 (35.0)” | “11 (27.5)” |
| Euphoric mood | “1 (2.6)” | “2 (5.1)” | “5 (12.5)” | “11 (27.5)” | “6 (15.0)” |
| Mydriasis | “1 (2.6)” | “1 (2.6)” | “7 (17.5)” | “8 (20.0)” | “4 (10.0)” |
| Hyperhidrosis | “0” | “1 (2.6)” | “4 (10.0)” | “9 (22.5)” | “5 (12.5)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.5-3"></a>

##### Most frequent dosing-day adverse events at 100 µg and 200 µg

> “On the dosing days, the most frequent AEs reported in the 100-µg and 200-µg dose groups were visual perceptual changes (illusion, pseudo-hallucination, hallucination) in 92.5% and 100% of participants, respectively, nausea in 40.0% and 60.0%, headache in 35.0% and 27.5%, and euphoric mood in 27.5% and 15.0%.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.5-4"></a>

##### Most common adverse events as stated in the company publication announcement, September 2025

> “MM120 had adverse events consistent with the expected effects of LSD including visual perceptual changes (illusion, pseudo-hallucination, and visual hallucination) occurring in 51.4%, 77.5%, 92.5%, 100%, and 10.3%; nausea in 7.7%, 27.5%, 42.5%, 65.0%, and 7.7%; and headache in 15.4%, 27.5%, 35.0%, 27.5%, and 23.1%, in the 25, 50, 100, 200 µg, and placebo groups, respectively.”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.8.5-5"></a>

##### Serious adverse events

> “One SAE occurred during the study when a participant in the 50-µg dose group was hospitalized for a panic attack that occurred 97 days after the dosing day and was deemed unrelated to the study drug.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “Participant received MM120 on 26 January 2023. On Study Day 98, the participant experienced an SAE of moderate panic attack requiring hospitalization. It was considered not related to treatment and recovered same day.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.5-6"></a>

##### Suicidal ideation and behavior

> “No participants engaged in self-injurious or suicidal behavior, which was assessed using the C-SSRS and AE reporting. There were no reports of suicidal ideation with intent or a plan during the sessions or throughout the trial. Participants with a history of suicidal ideation showed no increase in severity.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “As measured by C-SSRS, active SI without intent or plan was reported at week 12 by 1 placebo participant and at week 8 by 1 MM120 25 μg participant, both of whom had a history of similar or more severe SI.”
> “The site physician was involved in each case of reported or detected SI, and all cases were effectively assessed and managed on an outpatient basis.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.5-7"></a>

##### Suicidal ideation reported as an adverse event in the registry

| Arm | Affected / at risk (%) |
| --- | --- |
| Placebo | “1/39 (2.56%)” |
| Lysergide 25 μg | “1/39 (2.56%)” |
| Lysergide 50 μg | “2/40 (5.00%)” |
| Lysergide 100 μg | “2/40 (5.00%)” |
| Lysergide 200 μg | “0/40 (0.00%)” |

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.5-8"></a>

##### Adverse event collection period

> “AE collection will occur from the time informed consent is given until Week 12 (or early discontinuation) and will be recorded at each visit.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.5-9"></a>

##### Resolution of acute effects and time to meeting session-end criteria

> “Resolution of acute effects from MM120 was observed in more than 97% of participants at all MM120 doses by 12 hours after the dose was administered (eFigure 6 in Supplement 3). In the 100-µg dose group, 45.0% of participants met criteria to safely end the session at 8 hours, 70.0% at 9 hours, 87.5% at 10 hours, 90.0% at 11 hours, and 97.5% at 12 hours. All participants remained at the study site until 12 hours after the dosing session regardless of meeting criteria to safely end the session per the trial protocol (Supplement 1).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.5-10"></a>

##### Sponsor summary of tolerability

> “Virtually all AEs (99%) were mild-to-moderate in severity”
> “Minimal (2.5%) TEAEs led to study withdrawal”
> “One serious adverse event (SAE) was observed in the 50 μg dose group: panic attack on study day 98 that was deemed not related to treatment.”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.3.8.5-11"></a>

##### Pooled safety analysis including the phase 2b 100 µg and 200 µg arms

> “Multicenter, randomized, double-blind, dose-finding in participants with GAD”
> “Across all 4 studies, there were no treatment-related serious adverse events (AEs), hallucinogen persisting perception disorder, or deaths after treatment with DT120”
> “Similarly, there was no worsening of preexisting passive suicidal ideation, no active suicidal ideation or behaviors, and no evidence of session-induced suicidal ideation”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

The trial randomized 198 participants at 22 outpatient sites in the United States to a single dose of lysergide capsules (25, 50, 100, or 200 µg) or placebo, with 12 weeks of follow-up and no study-related psychotherapy. The phase 3 trials use an orally disintegrating tablet, so the phase 2b results were obtained with a different formulation.

- Primary analysis and reported effect size: the prespecified MCP-Mod primary analysis with multiple imputation gave a least-squares mean difference from placebo at Week 4 of −5.0 points (95% CI, −9.6 to −0.4) for 100 µg. The 7.6-point difference (Cohen d = 0.88) that company announcements report for Week 4 is the publication's secondary outcome at Week 4. The publication states that change in HAM-A score from baseline was analyzed by analysis of covariance without imputation (observed cases only), while missing primary end point data were imputed by multiple imputation; the registry results state that missing data were not imputed for non-key secondary efficacy endpoints.
- Multiplicity: only the primary and key secondary outcomes were controlled for type I error; other hypothesis tests, including the Week 12 difference of −7.7 points and the response and remission rates, were not adjusted for multiple comparisons.
- Functional unblinding: the authors state that the perceptible drug effects may have led to unblinding, and approximately 85% of participants correctly identified assignment to active treatment. Efficacy was rated by central raters blinded to protocol, treatment allocation, and visit.
- Dosing session monitors: two monitors were present throughout each session, and the authors state that confounding effects of interpersonal interactions remain a possibility.
- Missing data: 147 of 198 randomized participants (74.2%) completed the study, and the authors describe the dropout rate as slightly higher than in studies of similar molecules.
- Population: participants were physically healthy with limited psychiatric comorbidities, discontinued anxiolytic and antidepressant medications before dosing, and 83.0% were White; 18% received psychotherapy outside the trial.
- Sample size: 36 to 40 participants per arm in the full analysis set; analyses by sex and other characteristics were not conducted because of insufficient statistical power.
- Adverse event figures for visual perceptual changes, nausea, and headache in the company publication announcement differ from those in the journal article (for example, nausea at 100 µg 42.5% versus 40.0%).

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf); [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results); [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder); [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.9-2"></a>

#### Limitations stated in the publication

> “Despite dosing session monitors explicitly not providing a systematic psychotherapeutic intervention, confounding effects of interpersonal interactions remain a possibility.”
> “Second, the perceptible drug effects of MM120 may have led to unblinding, which could have influenced the outcomes.”
> “Third, the primary outcome and key secondary outcome were strictly controlled for type I error, but the other hypothesis tests were not adjusted for multiple comparisons. Fourth, the dropout rate, though similar across groups, was slightly higher than in studies of similar molecules.”
> “This higher dropout rate may be due to the 12-week duration of the trial, the required discontinuation of GAD medications, and the absence of an extension phase with opportunities for open-label treatment. Fifth, the participants were physically healthy with limited psychiatric comorbidities, potentially enhancing the tolerability of transient AEs. Sixth, the process of tapering participants from prohibited psychoactive medications ensured MM120 was assessed as a monotherapy; however, we did not address concomitant use of other pharmacotherapies. Seventh, some participants engaged in psychotherapy outside the trial, which may have affected dosing-day experiences and efficacy outcomes, though this was the case for only 18% of participants. Eighth, the study population was inclusive in terms of sex and age but was racially and ethnically less diverse than the general population of people with GAD.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.9-3"></a>

#### Limitations and caveats in the registry results

> “DSMs assisted and monitored participants which could be construed to have an independent therapeutic effect. So, DSMs were given training to not engage in psychotherapy with participants. There was a potential for unblinding so blinded independent central raters assessed the primary efficacy outcome.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

Additional sources: [Soares (2025)](https://pubmed.ncbi.nlm.nih.gov/40906492/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
